La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sopharma AD Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Sopharma AD.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	15.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Sopharma AD non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

BUL:SFA - Stime future degli analisti e dati finanziari passati (BGN Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	1,974	78	7	48	N/A
3/31/2024	1,932	93	-169	-124	N/A
12/31/2023	1,888	95	2	45	N/A
9/30/2023	1,832	81	-30	3	N/A
6/30/2023	1,787	91	45	77	N/A
3/31/2023	1,742	83	81	107	N/A
12/31/2022	1,672	71	86	110	N/A
9/30/2022	1,651	107	8	31	N/A
6/30/2022	1,655	101	-25	-1	N/A
3/31/2022	1,629	92	-67	-42	N/A
12/31/2021	1,611	89	-103	-76	N/A
9/30/2021	1,608	58	-128	-109	N/A
6/30/2021	1,527	41	-143	-117	N/A
3/31/2021	1,460	37	-177	-153	N/A
12/31/2020	1,446	30	-206	-179	N/A
9/30/2020	1,375	75	-193	-155	N/A
6/30/2020	1,353	85	-198	-160	N/A
3/31/2020	1,340	82	-187	-145	N/A
12/31/2019	1,288	87	-168	-128	N/A
9/30/2019	1,257	35	-177	-141	N/A
6/30/2019	1,231	30	-158	-123	N/A
3/31/2019	1,209	31	-156	-127	N/A
12/31/2018	1,188	28	-152	-124	N/A
9/30/2018	1,166	34	-141	-111	N/A
6/30/2018	1,125	32	-111	-90	N/A
3/31/2018	1,077	35	N/A	-73	N/A
12/31/2017	1,024	40	N/A	-58	N/A
9/30/2017	965	52	N/A	-53	N/A
6/30/2017	930	53	N/A	-89	N/A
3/31/2017	906	57	N/A	-67	N/A
12/31/2016	883	51	N/A	-69	N/A
9/30/2016	874	29	N/A	-32	N/A
6/30/2016	867	21	N/A	22	N/A
3/31/2016	878	23	N/A	50	N/A
12/31/2015	883	21	N/A	67	N/A
9/30/2015	883	24	N/A	61	N/A
6/30/2015	877	29	N/A	50	N/A
3/31/2015	860	17	N/A	36	N/A
12/31/2014	852	20	N/A	38	N/A
9/30/2014	833	19	N/A	38	N/A
6/30/2014	811	19	N/A	41	N/A
3/31/2014	793	24	N/A	56	N/A
12/31/2013	767	29	N/A	53	N/A
9/30/2013	738	30	N/A	45	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista SFA è superiore al tasso di risparmio ( 3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di SFA cresceranno più velocemente del mercato BG

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di SFA cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di SFA cresceranno più rapidamente del mercato BG.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di SFA cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SFA è previsto essere elevato tra 3 anni

Sopharma AD Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Price target decreased to лв3.48

Price target decreased to лв3.48

Price target lowered to лв3.24

Recent updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)

Independent Director recently bought лв331k worth of stock

Chairman recently bought лв124k worth of stock

First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Now 23% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Chairman recently sold лв527k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought лв338k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.4% yield

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

New minor risk - Share price stability

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

New minor risk - Shareholder dilution

Chairman recently bought лв72k worth of stock

Investor sentiment improves as stock rises 17%

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought лв81k worth of stock

Chairman recently sold лв1.1m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold лв297k worth of stock

New minor risk - Dividend sustainability

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Consensus EPS estimates increase by 83%

Price target increased to лв4.83

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Sopharma AD, Annual General Meeting, Jun 03, 2022

Less than half of directors are independent

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released

Chairman recently bought лв79k worth of stock

Price target decreased to лв3.48

Price target decreased to лв3.48

First quarter 2021 earnings released

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

New 90-day high: лв3.50

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

New 90-day high: лв3.26

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

New 90-day high: лв3.18

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

New 90-day high: лв3.16